N-pentyl-2-phenoxyacetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-pentyl-2-phenoxyacetamide
• 化学式: C₁₃H₁₉NO₂
• 分子量: 221.29
• InChiKey: TXNQPYBXIVYRLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• METHODS TO PREDICT BINDING AFFINITY OF TSPO IMAGING AGENTS TO TSPO
  申请人：Imperial Innovations Limited

  公开号：EP2718464A1

  公开（公告）日：2014-04-16
• Administration of 2-oxyacetamide compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting the depigmentation and/or bleaching thereof
  申请人：Rozot Roger

  公开号：US20080166310A1

  公开（公告）日：2008-07-10

  A regime or regimen for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for preventing and/or limiting the depigmentation and/or bleaching and/or for preventing and/or limiting the canities thereof, more particularly of human keratin fibers such as the hair, beard hair, moustache hair, the eyelashes and the eyebrows, includes administering to an individual in need of such treatment at least one 2-oxyacetamide compound of formula (I), or a salt and/or solvate thereof:
• [EN] CYCLIC TETRAPEPTIDE COMPOUND AND USE THEREOF<br/>[FR] COMPOSE TETRAPEPTIDE CYCLIQUE ET UTILISATION ASSOCIEE
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2003057722A2

  公开（公告）日：2003-07-17

  A cyclic tetrapeptide compound of the formula (I): wherein R1 is hydrogen; R2 is lower alkyl, aryl, optionally substituted ar(lower)alkyl, heterocyclic(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, lower alkylcarbamoyl(lower)alkyl or arylcarbamoyl(lower)alkyl; R3 and R4 are each independently hydrogen, lower alkyl, optionally substituted ar(lower)alkyl, optionally substituted heterocyclic(lower)alkyl or cyclo(lower)alkyl(lower)alkyl, or R3 and R4 are linked together to form lower alkylene or condensed ring, or one of R3 and R4 is linked to the adjacent nitrogen atom to form a ring; R5 is lower alkylene or lower alkenylene, Y is [wherein RY1 is hydrogen, halogen or optionally protected hydroxy, RY2 is hydrogen, halogen, lower alkyl or phenyl, and RY3 is hydrogen or lower alkyl]; R8 is hydrogen or lower alkyl; and n is an integer of 1 or 2, or a salt thereof.
• [EN] METHODS TO PREDICT BINDING AFFINITY OF TSPO IMAGING AGENTS TO TSPO<br/>[FR] PROCÉDÉS DE PRÉDICTION DE L'AFFINITÉ DE LIAISON À TSPO D'AGENTS D'IMAGERIE
  申请人：IMP INNOVATIONS LTD

  公开号：WO2012168697A1

  公开（公告）日：2012-12-13

  A method for aiding in selecting or adjusting a dose of TSPO imaging or therapeutic agent for use with a subject, the method comprising the step of determining the subject's genotype for TSPO rs6971. A TSPO imaging or therapeutic agent for use in TSPO imaging or therapy in a subject, wherein the subject is a subject whose genotype at TSPO polymorphism position rs6971 is determined. The subject's genotype for TSPO may be taken into account when assessing the results of the TSPO imaging, for example normalising the subject's determined measure of binding of the TSPO agent to take account of the subject's determined genotype. The subject's genotype for TSPO may be taken into account when choosing the TSPO agent and/or the dose of TSPO agent. The subject may be a subject who has been determined to have genotype CC or CT at TSPO polymorphism position rs6971, for example when using a TSPO agent that binds with higher affinity to Aia147TSPO than to Thr147TSPO.